Cargando…

S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY

BACKGROUND: There is limited information on patient’s perspective on choice of long-acting injectable (LAIs) or oral antipsychotic pills used in the management of schizophrenia. Assessing factors that determine patients’ preferences for LAI or oral antipsychotics could help understand their expectat...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackwood, Clifton, Sanga, Panna, Nuamah, Isaac, Keenan, Alexander, Singh, Arun, Mathews, Maju, Gopal, Srihari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234552/
http://dx.doi.org/10.1093/schbul/sbaa031.274
_version_ 1783535790079344640
author Blackwood, Clifton
Sanga, Panna
Nuamah, Isaac
Keenan, Alexander
Singh, Arun
Mathews, Maju
Gopal, Srihari
author_facet Blackwood, Clifton
Sanga, Panna
Nuamah, Isaac
Keenan, Alexander
Singh, Arun
Mathews, Maju
Gopal, Srihari
author_sort Blackwood, Clifton
collection PubMed
description BACKGROUND: There is limited information on patient’s perspective on choice of long-acting injectable (LAIs) or oral antipsychotic pills used in the management of schizophrenia. Assessing factors that determine patients’ preferences for LAI or oral antipsychotics could help understand their expectations from the treatment and reduce potential barriers to LAI use in schizophrenia. METHODS: Post-hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate in patients with schizophrenia. Data from the Medication Preference Questionnaire, administered to patients on day 1 (baseline; open-label stabilization phase), were used. The questionnaire includes 4 sets of items: (1) reasons for general treatment preference based on goals/outcomes and preference for LAI vs pills based on (2) personal experience (3) injection-site (4) dosing frequency. A logistic regression analysis was performed to assess the effect of baseline variables on preference for LAIs or pills. RESULTS: Patients who preferred LAIs identified these outcomes as important: “I feel more healthy” (57%), “I can get back to my favorite activities” (56%), “I don’t have to think about taking my medicines” (54%). Most common reasons for medication preference (LAI vs pills) were: “LAIs/pills are easier for me” (67% vs 18%), “more in control/don’t have to think about taking medicine” (64% vs 14%), “less pain/sudden symptoms” (38% vs 18%) and “less embarrassed” (0% vs 46%). Majority of patients (59%) preferred deltoid over gluteal injections: (reasons: faster administration [63%], easier [51%], less embarrassing [44%]). 50% of patients preferred 3-monthly over 1-monthly (38%) or every day (3%) dosing (reasons: fewer injections [96%], fewer injections are less painful [84%], fewer doctor visits [80%]). In the logistic regression analysis (n=1402), 77% of patients preferred LAI over pills and culture and race appeared to play a role in this preference. DISCUSSION: Patient empowerment and quality-of-life-related goals were important for patients who preferred LAI antipsychotics and when given an option, patients preferred less-frequent, quarterly injections over monthly injections and daily oral medications.
format Online
Article
Text
id pubmed-7234552
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72345522020-05-23 S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY Blackwood, Clifton Sanga, Panna Nuamah, Isaac Keenan, Alexander Singh, Arun Mathews, Maju Gopal, Srihari Schizophr Bull Poster Session I BACKGROUND: There is limited information on patient’s perspective on choice of long-acting injectable (LAIs) or oral antipsychotic pills used in the management of schizophrenia. Assessing factors that determine patients’ preferences for LAI or oral antipsychotics could help understand their expectations from the treatment and reduce potential barriers to LAI use in schizophrenia. METHODS: Post-hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate in patients with schizophrenia. Data from the Medication Preference Questionnaire, administered to patients on day 1 (baseline; open-label stabilization phase), were used. The questionnaire includes 4 sets of items: (1) reasons for general treatment preference based on goals/outcomes and preference for LAI vs pills based on (2) personal experience (3) injection-site (4) dosing frequency. A logistic regression analysis was performed to assess the effect of baseline variables on preference for LAIs or pills. RESULTS: Patients who preferred LAIs identified these outcomes as important: “I feel more healthy” (57%), “I can get back to my favorite activities” (56%), “I don’t have to think about taking my medicines” (54%). Most common reasons for medication preference (LAI vs pills) were: “LAIs/pills are easier for me” (67% vs 18%), “more in control/don’t have to think about taking medicine” (64% vs 14%), “less pain/sudden symptoms” (38% vs 18%) and “less embarrassed” (0% vs 46%). Majority of patients (59%) preferred deltoid over gluteal injections: (reasons: faster administration [63%], easier [51%], less embarrassing [44%]). 50% of patients preferred 3-monthly over 1-monthly (38%) or every day (3%) dosing (reasons: fewer injections [96%], fewer injections are less painful [84%], fewer doctor visits [80%]). In the logistic regression analysis (n=1402), 77% of patients preferred LAI over pills and culture and race appeared to play a role in this preference. DISCUSSION: Patient empowerment and quality-of-life-related goals were important for patients who preferred LAI antipsychotics and when given an option, patients preferred less-frequent, quarterly injections over monthly injections and daily oral medications. Oxford University Press 2020-05 2020-05-18 /pmc/articles/PMC7234552/ http://dx.doi.org/10.1093/schbul/sbaa031.274 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Session I
Blackwood, Clifton
Sanga, Panna
Nuamah, Isaac
Keenan, Alexander
Singh, Arun
Mathews, Maju
Gopal, Srihari
S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
title S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
title_full S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
title_fullStr S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
title_full_unstemmed S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
title_short S208. COMPARISON OF MEDICATION PREFERENCE FOR LONG-ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA: ANALYSIS OF A PATIENT-REPORTED QUESTIONNAIRE FROM A DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY
title_sort s208. comparison of medication preference for long-acting injectable versus oral antipsychotics in patients with schizophrenia: analysis of a patient-reported questionnaire from a double-blind randomized controlled study
topic Poster Session I
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234552/
http://dx.doi.org/10.1093/schbul/sbaa031.274
work_keys_str_mv AT blackwoodclifton s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy
AT sangapanna s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy
AT nuamahisaac s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy
AT keenanalexander s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy
AT singharun s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy
AT mathewsmaju s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy
AT gopalsrihari s208comparisonofmedicationpreferenceforlongactinginjectableversusoralantipsychoticsinpatientswithschizophreniaanalysisofapatientreportedquestionnairefromadoubleblindrandomizedcontrolledstudy